Identification of BCR::ABL1 Mutations by Digital PCR in CML

计划入组 150 人 · 首次发布于 2025 年 9 月 5 日

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

计划入组 32 人 · 首次发布于 2022 年 4 月 1 日

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

计划入组 155 人 · 首次发布于 2016 年 2 月 24 日

Asciminib(Scemblix)

C₂₀H₁₈ClF₂N₅O₃

BCR-ABL(Theseus)

BCR-Abl inhibitor(Nanjing Sanhome Pharmaceutical)

Ably Medical AS

Norway

ABLE HUMAN MOTION S.L.

Spain

ABL Bio, Inc.

South Korea

Digital PCR Outperforms Standard RT-qPCR in Detecting Residual BCR::ABL1 in CML Patients, Enabling Better TKI Discontinuation Decisions

Asciminib Demonstrates Durable Efficacy and Safety in Heavily Pretreated CML-CP Patients

FDA Approves Scemblix (asciminib) for First-Line Treatment of Chronic Myelogenous Leukemia